Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

Download as PDF

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic C/D ring of an analog of the company’s lantibiotic compound, Mutacin 1140. The study, titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” was published in the recent issue (volume 25, Issue 11) of Journal of Peptide Science.

“We continue to advance our understanding of how to best manipulate and expand our lantibiotic library, particularly our new semi-synthetic homologs of Mutacin 1140, in order to create new ways of fighting antibiotic-resistant infections and expand to novel indications,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. “This publication provides us with additional insight on how to expand our pipeline by chemical derivatization, which we hope ultimately may result in the development of compounds with entirely different properties and a broader spectrum of activity, to include Gram-negative infections.”

The full study can be accessed via https://onlinelibrary.wiley.com/doi/full/10.1002/psc.3214

About Lantibiotics

Lantibiotics are a class of antibiotic compounds with a novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is currently pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial targeting Clostridium difficile associated disease, the most prevalent hospital-acquired infection.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Oragenics, Inc.
Corporate:
Michael Sullivan, 813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investors:
John Marco
Managing Director
CORE IR
310-819-2948
johnm@coreir.com

Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.

Released November 15, 2019